| Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC SS Ramalingam, J Vansteenkiste, D Planchard, BC Cho, JE Gray, Y Ohe, ... New England Journal of Medicine 382 (1), 41-50, 2020 | 2531 | 2020 |
| Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ... New England Journal of Medicine 383 (18), 1711-1723, 2020 | 1637 | 2020 |
| Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ... The lancet oncology 21 (2), 271-282, 2020 | 1626 | 2020 |
| First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open … L Paz-Ares, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, ... The Lancet Oncology 22 (2), 198-211, 2021 | 1205 | 2021 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017 | 799 | 2017 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (5), 235-251, 2017 | 701 | 2017 |
| Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer SS Ramalingam, JCH Yang, CK Lee, T Kurata, DW Kim, T John, ... Journal of Clinical Oncology 36 (9), 841-849, 2018 | 579 | 2018 |
| Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ... The Lancet Oncology 21 (2), 261-270, 2020 | 475 | 2020 |
| Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC M Tsuboi, RS Herbst, T John, T Kato, M Majem, C Grohé, J Wang, ... New England Journal of Medicine 389 (2), 137-147, 2023 | 371 | 2023 |
| Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study VA Papadimitrakopoulou, YL Wu, JY Han, MJ Ahn, SS Ramalingam, ... Annals of Oncology 29, viii741, 2018 | 270 | 2018 |
| Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer: updated results from the phase III randomized ADAURA trial RS Herbst, YL Wu, T John, C Grohe, M Majem, J Wang, T Kato, ... Journal of Clinical Oncology 41 (10), 1830-1840, 2023 | 262 | 2023 |
| Molecular predictive and prognostic markers in non-small-cell lung cancer LE Coate, T John, MS Tsao, FA Shepherd The lancet oncology 10 (10), 1001-1010, 2009 | 257 | 2009 |
| Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of … T John, G Liu, MS Tsao Oncogene 28 (1), S14-S23, 2009 | 249 | 2009 |
| Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis VA Papadimitrakopoulou, TS Mok, JY Han, MJ Ahn, A Delmonte, ... Annals of Oncology 31 (11), 1536-1544, 2020 | 244 | 2020 |
| Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors PL Chia, P Mitchell, A Dobrovic, T John Clinical epidemiology, 423-432, 2014 | 221 | 2014 |
| Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP M Lu, H Breyssens, V Salter, S Zhong, Y Hu, C Baer, I Ratnayaka, ... Cancer cell 23 (5), 618-633, 2013 | 201 | 2013 |
| The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non–small cell lung cancer T John, D Kohler, M Pintilie, N Yanagawa, NA Pham, M Li, D Panchal, ... Clinical cancer research 17 (1), 134-141, 2011 | 196 | 2011 |
| Nivolumab (NIVO)+ ipilimumab (IPI)+ 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell … M Reck, TE Ciuleanu, MC Dols, M Schenker, B Zurawski, J Menezes, ... Journal of Clinical Oncology 38 (15_suppl), 9501-9501, 2020 | 192 | 2020 |
| First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update M Reck, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, ... ESMO open 6 (5), 100273, 2021 | 184 | 2021 |
| BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival EF Lee, TJ Harris, S Tran, M Evangelista, S Arulananda, T John, ... Cell death & disease 10 (5), 342, 2019 | 181 | 2019 |
